Article

Knowledge-based mechanistic modeling accurately predicts disease progression with gefinitib in EGFR-mutant lung adenocarcinoma

2023-01-09

Abstract excerpt

<title>Abstract</title> <p>Lung adenocarcinoma (LUAD) is associated with a low survival rate at advanced stages. Although the development of targeted therapies has improved the survival of LUAD patients with identified and specific genetic alterations, such as mutations on the epidermal growth factor receptor (EGFR), the emergence of tumor resistance remains a threat to patient survival and calls for the developm...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2c58a779-c2ae-507e-b6de-fc0379a7bdba
DOI: 10.21203/rs.3.rs-2405647/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Knowledge-based mechanistic modeling accurately predicts disease progression with gefinitib in EGFR-mutant lung adenocarcinomaDOI 10.21203/rs.3.rs-2405647/v1Read

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug-Disease Mechanistic Model Approach in Egfr-Mutant Lung AdenocarcinomaSemantic proximity Read

A novel artificial lung organoid for simulating a patient derived adenocarcinoma of lung for personalized oncologySemantic proximity Read

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patientsSemantic proximity Read

Multivariable Modelling Reveals EGFR Copy Number as an Independent Predictor of Survival in LUADSemantic proximity Read

Empirical methods for the validation of Time-To-Event mathematical models taking into account uncertainty and variability: Application to EGFR+ Lung AdenocarcinomaSemantic proximity Read

Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.Semantic proximity Read

Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.Semantic proximity Read

An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors.Semantic proximity Read

Computational Methods for the Analysis and Prediction of EGFR-Mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects.Semantic proximity Read

Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth.Semantic proximity Read

Cancerous time estimation for interpreting the evolution of lung adenocarcinoma.Semantic proximity Read

Mathematical Model of Intrinsic Drug Resistance in Lung Cancer.Semantic proximity Read